Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study

The Lancet Infectious Diseases

Volumn 12, Issue 8, 2012, Pages 627-634

  Georgousakis, Melina ^a   Jayasinghe, Sanjay ^a   Brotherton, Julia ^b,c   Gilroy, Nicole ^d,e   Chiu, Clayton ^a,c   Macartney, Kristine ^a,c,f  

^a NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

^b Victorian Cervical Cytology Registry Melbourne   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e Blood and Marrow Transplant (BMT) Network   (Australia)

^f CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT HEALTH; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; HEALTH PROGRAM; HOMOSEXUALITY; HUMAN; MANAGEMENT; MASS SCREENING; MEN'S HEALTH; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEX RATIO; VACCINATION; VIRUS LOAD; WART VIRUS;

ADOLESCENT; ADULT; AUSTRALIA; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; VACCINATION; YOUNG ADULT;

EID: 84864131684     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70031-2     Document Type: Review

References (90)

1. de Sanjose S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
2. Ward KF, Menzies RI, Quinn HE, Campbell-Lloyd S School-based vaccination in NSW. NSW Public Health Bull 2010, 21:237-242.
3. National human papillomavirus (HPV) vaccination program register Victorian Cytology Service, (accessed Jan 31, 2012). http://www.hpvregister.org.au/.
4. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011, 60:1705-1708. Centers for Disease Control.
5. An advisory committee statement: update on human papillomavirus (HPV) vaccines: Canadian communicable disease report National Advisory Committee on Immunization (NACI), (accessed Feb 20, 2012). http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-8/index-eng.php.
6. Erickson L, De Wals P, Farand L An analytical framework for immunization programs in Canada. Vaccine 2005, 23:2470-2476.
7. Kimman TG, Boot HJ, Berbers GAM, Vermeer-de Bondt PE, Ardine de Wit G, de Melker HE Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine 2006, 24:4769-4778.
8. Piso B, Wild C Decision support in vaccination policies. Vaccine 2009, 27:5923-5928.
9. Vaccines for the 21st century: a tool for decisionmaking 2000, Committee to Study priorities for Vaccine Development, Division of Health Promotion and Disease Prevention Institute of Medicine, National Academies Press, Washington, DC.
10. King L, Lévy-Bruhl D, O'Flanagan D, et al. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey. Euro Surveill 2008, 13:18954.
11. Lévy-Bruhl D, Bousquet V, King L, et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur J Cancer 2009, 45:2709-2713.
12. Smith JS, Melendy A, Rana RK, Pimenta JM Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43:S5-25.
13. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011, 377:932-940.
14. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health 2011, 48:540-552.
15. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008, 17:2036-2043.
16. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV Detection in Men Study. J Infect Dis 2007, 196:1146-1152.
17. Vajdic CM, van Leeuwen MT, Jin F, et al. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sex Transm Infect 2009, 85:330-335.
18. Vardas E, Giuliano AR, Goldstone S, et al. External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. J Infect Dis 2011, 203:58-65.
19. Bleeker MCG, Heideman DAM, Snijders PJF, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009, 27:141-150.
20. Crispen PL, Mydlo JH Penile intraepithelial neoplasia and other premalignant lesions of the penis. Urol Clin North Am 2010, 37:335-342.
21. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:162-236.
22. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J Cancers attributable to human papillomavirus infection. Sex Health 2010, 7:244-252.
23. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute state of the science meeting, November 9-10, 2008, Washington, DC. Head Neck 2009, 31:1393-1422.
24. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect 2010, 86:181-186.
25. Cancer AIHW, (accessed Jan 31, 2012). http://www.aihw.gov.au/cancer/data/datacubes/index.cfm.
26. Cancer in Australia: an overview, 2008 2008, AIHW, Australasian Association of Cancer Registries, Australian Institute of Health and Welfare, Canberra.
27. Jin F, Stein AN, Conway EL, et al. Trends in anal cancer in Australia, 1982-2005. Vaccine 2011, 29:2322-2327.
28. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011, 29:4294-4301.
29. Hong AM, Grulich AE, Jones D, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine 2010, 28:3269-3272.
30. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004, 190:2070-2076.
31. Van der Snoek EM, Niesters HG, Mulder PG, Van Doornum GJ, Osterhaus AD, Van der Meijden WI Human papillomavirus infection in men who have sex with men participating in a Dutch gay-cohort study. Sex Transm Dis 2003, 30:639-644.
32. Nyitray AG, Villa L, Lazcano Ponce E, Abrahamsen M, Papenfuss M, Giuliano AR Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross national study. J Infect Dis 2010, 201:1498-1508.
33. de Pokomandy A, Rouleau D, Ghattas G, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG Cohort Study. J Infect Dis 2009, 199:965-973.
34. Cranston RD Anal cancer prevention: how we are failing men who have sex with men. Sex Transm Infect 2008, 84:417-419.
35. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987, 317:973-977.
36. Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982, 247:1988-1990.
37. Parkin DM, Bray F Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24:S11-S25.
38. Smith A, Rissel CE, Richters J, Grulich AE, Visser RO Sex in Australia: sexual identity, sexual attraction and sexual experience among a representative sample of adults. Aust NZ J Public Health 2003, 27:138-145.
39. Frisch M, Smith E, Grulich A, Johansen C Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am J Epidemiol 2003, 157:966-972.
40. Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2010, 39:166-181.
41. Lacey CJN, Lowndes CM, Shah KV Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24:35-41.
42. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011, 364:401-411.
43. Palefsky JM. Quadrivalent HPV vaccine efficacy against anal intraepithelial neoplasia in men having sex with men. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); Monte Carlo, Monaco; Feb 17-20, 2010.
44. Clinical review of biologics license application supplement STN#125126/1297.0-male indication for GARDASIL Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Vaccines and Related Product Applications, (accessed Jan 31, 2012). http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190977.pdf.
45. Briefing Document for the Vaccines and Related Biologicals Products Advisory Committee (VRBPAC): anal cancer indication for Gardasil Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Vaccines and Related Product Applications, (accessed Jan 31, 2012). http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/.
46. Scholefield JH, Harris D, Radcliffe A Guidelines for management of anal intraepithelial neoplasia. Colorectal Dis 2011, 13:3-10.
47. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005, 58:946-950.
48. Rowhani-Rahbar A, Carter JJ, Hawes SE, et al. Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 2009, 200:1452-1455.
49. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26:201-209.
50. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118:2135-2145.
51. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009, 44:33-40.
52. Schiller JT, Day PM, Kines RC Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010, 118:S12-S17.
53. Stanley M, Lowy DR, Frazer I Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006, 24:S106-S113.
54. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26:6844-6851.
55. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
56. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 2011, 7:240-248.
57. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
58. Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29:2011-2014.
59. Palefsky JM. Efficacy of Gardasil against external genital lesions due to 14 HPV types in men. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); Monte Carlo, Monaco; Feb 17-20, 2010.
60. Gillison ML, Chaturvedi AK, Lowy DR HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113:3036-3046.
61. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009, 27:5612-5619.
62. Moscicki B, Wheeler C, Romanowski B. Anamnestic response elicited by a fourth dose of the HPV-16/18 AS04-adjuvanted vaccine in young women European Research Organisation on Genital Infection and Neoplasia (EUROGIN); Monte Carlo, Monaco; Feb 17-20, 2010.
63. Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25:4931-4939.
64. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 2010, 29:95-101.
65. Bonanni P, Cohet C, Kjaer SK, et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD®. Vaccine 2010, 28:4719-4730.
66. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2010, 11:39-44.
67. Smith MA, Lew JB, Walker RJ, Brotherton JML, Nickson C, Canfell K The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011, 29:9112-9122.
68. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29:8443-8450.
69. Jit M, Choi YH, Edmunds WJ Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:1-12.
70. Kim JJ, Goldie SJ Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:1-10.
71. Taira AV, Neukermans CP, Sanders GD Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10:1915-1923.
72. Ubel PA, Hirth RA, Chernew ME, Fendrick AM What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 2003, 163:1637-1641.
73. Devlin N, Parkin D Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004, 13:437-452.
74. Elbasha EH, Dasbach EJ Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28:6858-6867.
75. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010, 28:4091-4102.
76. Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007, 4:165-175.
77. Nolan TM The Australian model of immunization advice and vaccine funding. Vaccine 2010, 28:A76-A83.
78. George B, Harris A, Mitchell A Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001, 19:1103-1109.
79. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 4.3) Pharmaceutical Benefits Advisory Committee, (accessed Jan 31, 2012). http://www.health.gov.au/internet/main/publishing.nsf/content/AECB791C29482920CA25724400188EDB/$File/PBAC4.3.2.pdf.
80. November 2011 PBAC outcomes-positive recommendations Australian Government Department of Health and Ageing, (accessed Jan 31, 2012). http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2011-11/positive-recommendations.
81. PBAC outcomes by meeting: March 2011 PBAC outcomes-1st time decisions not to recommend Australian Government Department of Health and Ageing, (accessed Jan 31, 2012). http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-mar11-first-time-rejections.
82. Kim JJ Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010, 10:845-852.
83. Simatherai D, Bradshaw CS, Fairley CK, Bush M, Heley S, Chen MY What men who have sex with men think about the human papillomavirus vaccine. Sex Transm Infect 2009, 85:148-149.
84. Gerend MA, Barley J Human papillomavirus vaccine acceptability among young adult men. Sex Transm Dis 2009, 36:58-62.
85. Ferris DG, Waller JL, Miller J, et al. Variables associated with human papillomavirus (HPV) vaccine acceptance by men. J Am Board Fam Med 2009, 22:34-42.
86. Agius PA, Pitts MK, Smith AMA, Mitchell A Human papillomavirus and cervical cancer: Gardasil® vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine 2010, 28:4416-4422.
87. Pitts MK, Heywood W, Ryall R, et al. Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women. Sex Health 2010, 7:299-303.
88. Brewer NT, Ng TW, McRee AL, Reiter PL Men's beliefs about HPV-related disease. J Behav Med 2010, 33:274-281.
89. Hernandez BY, Wilkens LR, Thompson PJ, et al. Acceptability of prophylactic human papillomavirus vaccination among adult men. Hum Vaccin 2010, 6:467-475.
90. Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex Transm Dis 2010, 37:197-203.